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osting by EAbstract Background aim of the study: Patent ductus arteriosus (PDA), a common ﬁnding among
premature infants, is conventionally treated by intravenous indomethacin. Intravenous ibuprofen
was recently shown to be as effective and to have fewer adverse reactions in preterm infants. If
equally effective, then oral ibuprofen for PDA closure would have several important advantages
over the intravenous route. This study was designed to determine whether oral ibuprofen treatment
is efﬁcacious and safe in closure of a PDA in premature infants.
Patients and methods: Thirty-three premature group I (study group) were treated with ibuprofen
10 mg/kg administered through a feeding tube. Thirty-three premature group II (control group)
receive placebo the two imaging procedures were again performed 24 h after each ibuprofen dose.
When the PDA was still hemodynamically signiﬁcant, as demonstrated by echocardiography, and
there was no evidence of deterioration in brain ultrasonography, a second dose of ibuprofen 5 mg/
kg (placebo for control) was administered. A third equivalent dose was given after another 24 h if
necessary. Cranial ultrasound was repeated 1 week after the last ibuprofen dose and again before
discharge from the ward. Hematochemical analysis was preformed daily in the unit during the ﬁrst
days of life.
Results: In the study group the rate of PDA closure was 93.9% (31 of 33 cases) while in the control
group the rate of PDA closure was 30.3% (10 of 33 cases) with signiﬁcant difference in between.com (S. Ghanem).
ity. All rights reserved. Peer-
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8 S. Ghanem et al.There was no reopening of the ductus after closure had been achieved. No infant required surgical
ligation of the ductus in study group while in the control group 24.2% (8 of 33 cases) were required
surgical ligation (Table 2). Twenty-one newborns were treated with 1 dose of ibuprofen, 9 were trea-
ted with 2 doses, and the remaining 3 were treated with 3 doses.
Conclusion: Oral ibuprofen is an effective and safe alternative to intravenous ibuprofen for PDA
closure in premature infants.
ª 2010 King Saud University. All rights reserved.1. Introduction
The incidence of patent ductus arteriosus (PDA) in premature
infants who weigh between 500 and 1500 g at birth is approx-
imately 30% on the third day of life (The Vermont-Oxford
Trials, 1993).
PDA is associated with increased risks of intraventricular
hemorrhage (IVH), necrotizing enterocolitis (NEC), chronic
lung disease (CLD), and death Gersony et al., 2004; Cotton
et al., 2001. Therefore, closure of a hemodynamically signiﬁ-
cant PDA is indicated.
Intravenous indomethacin is the conventional pharmaco-
logic treatment for promoting closure of a patent ductus in
premature infants. However, concern remains regarding the
safety of indomethacin, which affects renal, gastrointestinal,
and cerebral perfusion and may lead to complications such
as transient or permanent renal dysfunction (Krueger et al.,
2002; Hammerman et al., 2005), necrotizing enterocolitis, gas-
trointestinal hemorrhage (Van Bel et al., 2005), and reduced
cerebral intracellular oxygenation (Varvarigou et al., 2006).
Intravenous ibuprofen was recently shown to be as effective
for the closure of patent ductus arteriosus in premature infants
(Chemtob et al., 2004, 2000, 2007), without reducing mesen-
teric, renal (Mosca et al., 2006), or cerebral (Malcolm et al.,
2005) blood ﬂow. However, the intravenous form of ibuprofen
is not available in Saudi Arabia, whereas, the oral suspension
form is widely used for antipyretic treatment in children.
Therefore, we investigated the possibilities of using oral ibu-
profen for the treatment of PDA in premature newborn in-
fants. Oral ibuprofen for PDA closure would have several
important advantages over the intravenous route. (1) Intrave-
nous ibuprofen is not available in the Saudi Arabia and many
other countries, (2) the required oral dose is of minimal volume
(0.25–0.5 mL for infants who weigh 500–1000 g), (3) oral
administration is extremely simple, and (4) the oral form of
the drug is less expensive than the intravenous one. This study
was designed to determine whether oral ibuprofen treatment is
efﬁcacious and safe in closure of a PDA in premature infants.
2. Patients and methods
Sixty-six premature newborns that were treated at the neonatal
intensive care unit at Al-Jedaani Hospital, Saudi Arabia be-
tween November 2006 and April 2008 were recruited prospec-
tively. The infants were enrolled in the study only after written
parental consent had been obtained and divided into two groups
 Group I study group that receive ibuprofen.
 Group II control group receive placebo.
Neonates who were admitted to the study were enrolled
when the following criteria were met:(1) Gestational age <32 weeks and <1500 g.
(2) Postnatal age between 48 and 96 h.
(3) RDS on chest radiograph necessitating treatment with
surfactant, mechanical ventilation, and need for oxygen
supplementation above 25%.
(4) Echocardiographic evidence of hemodynamically signif-
icant PDA (left atrium/aortic root diameter ratio >1.4
or ductal size >1.5 mm) (de Vries et al., 2002).
Exclusion criteria included:
(1) Presence of major congenital anomalies.
(2) IVH of grade 3 according to the classiﬁcation by Papile
et al. (1998) within the previous 24 h.
(3) Serum creatinine level P1.5 mg%.
(4) Serum urea nitrogen concentration >50 mg%.
(5) Platelet count 660,000/mL3.
(6) A tendency to bleed (deﬁned by the presence of hematu-
ria, blood in the endotracheal aspirate, gastric aspirate,
or stools and/or oozing from puncture sites).
(7) Hyperbilirubinemia necessitating exchange transfusion.
3. Study design
Sixty-six infants who were born between November 2006 and
April 2008 and met the entry criteria ﬁrst underwent echocar-
diography and cranial ultrasonography, after which 33 prema-
ture group I (study group) were treated with ibuprofen 10 mg/
kg administered through a feeding tube. Thirty-three prema-
ture groups II (control group) receive placebo the two imaging
procedures were again performed 24 h after each ibuprofen
dose. When the PDA was still hemodynamically signiﬁcant,
as demonstrated by echocardiography, and there was no evi-
dence of deterioration in brain ultrasonography, a second dose
of ibuprofen 5 mg/kg (placebo for control) was administered.
A third equivalent dose was given after another 24 h if neces-
sary. Cranial ultrasound was repeated 1 week after the last ibu-
profen dose and again before discharge from the ward.
Hematochemical analysis was preformed daily in the unit dur-
ing the ﬁrst days of life.
RDS was treated with respiratory support (intermittent
mechanical ventilation), oxygen supplements, and surfactant
100 mg/kg. Treatment of PDA in preterm infants with RDS
is indicated before a signiﬁcant left-to-right shunting occurs
(Gersony et al., 2004; Hammerman et al., 2005). Surfactant
was administered during the ﬁrst 24 h on the basis of the need
for oxygen and respiratory support, i.e., fraction of inspired
oxygen P40% and mean airway pressure of P8, and chest
radiographs compatible with the diagnosis of RDS. Prophylac-
tic antibiotics were started on admission and stopped after
5 days if blood cultures were negative. Birth weight, gesta-
tional age, and clinical outcomes were recorded prospectively.
Effect of oral ibuprofen on patent ductus arteriosusin premature newborns 94. Echocardiography
Color Doppler echocardiography was performed on all infants
who were clinically suspected of having PDA, using SSD-Al-
pha 7 Aloka color Doppler ultrasound machine equipped with
UST 52108 pediatric cardiac probe having frequency 1–
15 MHz with tissue harmonic imaging technology, all infants
underwent a complete 2D, M-mode and color Doppler imag-
ing. This was conducted by a cardiologist who was blind to
the child’s name and the treatment being given. Patients with
clinical signs of PDA such as tachycardia (>160 beats/min),
presence of a murmur, and bounding pulses were eligible for
the study and underwent an echocardiographic evaluation be-
fore entry to the study (Mahony et al., 1999). PDA was consid-
ered echocardiographically signiﬁcant when the ductal size was
>1.5 mm or the left atrial-to-aortic root ratio was >1.4. We
evaluated these parameters before the ﬁrst dose and 24 h after
each dose of ibuprofen, never exceeding 3 doses in total.
5. Cranial ultrasonography
Cranial ultrasound scans were performed by radiologist using
SSD-Alpha 7 Aloka color Doppler ultrasound machine
equipped with UST 9120 pediatric transcranial electronic con-
vex probe having frequency 1–15 MHz before treatment was
started, after each dose of ibuprofen, before any additionalTable 2 Efﬁcacy of treatment by ibuprofen.
Variable Study group (no. = 33)
Age at start of treatment (d) 2.5 ± 0.6
Number of closed PDA (%) 31/33 (93.9%)
Number of ibuprofen doses 1.45 ± 0.67 (range: 1–3)
Surgical ligation 0
* Insigniﬁcant.
** Signiﬁcant.
Table 1 Baseline characteristics of the study infants.
Diseased group (no. = 33
Birth weight (g) 1035 ± 353 (range: 680–1
Gestational age (week) 28.8 ± 2.8 (range: 27–32)
Antenatal indomethacin (n) 0
Antenatal glucocorticoids (n) 14
Surfactant treatment (n) 16
1 Dose 6
2 Doses 10
3 Doses 3
Mechanical ventilation (n) 9 (27.3%)
Mean airway pressure (cm H2O) 10.4 ± 2.3
Inspired oxygen (%) 40 ± 13 (range: 25–70)
IVH (n) grade 1 5 (15.2%)
IVH (n) grade 2 3 (9%)
IVH (n) grade 3 3 (9%)
Ductal diameter (mm) 2.3 ± 0.83
Degree of ductal shunting (n)
Moderate 26 (78.8%)
Severe 7 (21.2%)
* Insigniﬁcant.doses, 1 week after the last dose, and before discharge from
the ward. The study infants were assessed for IVH (grades
1–4) Papile et al., 1998; Van Overmeire et al., 2007.
5.1. Statistical analysis
Continuous data, such as weight, gestational age, various
treatment modalities, IVH, and age at start of treatment, were
presented as mean ± standard deviation. Changes in serum
creatinine concentrations were compared using t-test.
6. Results
A total of 250 premature infants at gestational age <32 weeks
and birth weight <1500 g were admitted in the Al-Jedaani
Neonatal Intensive Care Unit during the study period. Sixty-
six premature of them were legible for entry in the study and
underwent an echocardiographic-Doppler ultrasound evalua-
tion at the age of 48–96 h, and divided into two groups:
 Group I study group that receive ibuprofen.
 Group II control group receive placebo.
Fluid intake began at 70–80 mL/kg/d and was increased by
20–30 mL/kg/d to a maximum of 160 mL/kg/d by the end of
the ﬁrst week, adjusted according to body weight. Most pa-Control group (no. = 33) p-Value
2.4 ± 0.9 >0.05*
10/33 (30.3%) <0.001**
8/33 (24.2%) <0.001**
) Control group (no. = 33) p-Value
500) 1047 ± 403 >0.05*
28.9 ± 2.7 >0.05*
0
15 >0.05*
17 >0.05*
7 >0.05*
11 >0.05*
2 >0.05*
10 (30.3%) >0.05*
10.5 ± 2.4 >0.05*
41 ± 14 (range: 26–70) >0.05*
4 (12.1%) >0.05*
2 (6.1%) >0.05*
2 (6.1%) >0.05*
2.2 ± 0.87 >0.05*
27 (81.9%) >0.05*
6 (18.1%) >0.05*
10 S. Ghanem et al.tients received packed red blood cells as well as fresh-frozen
plasma transfusion. Hypotension was treated with ﬂuid
replacement. Dopamine was used in cases in which ﬂuid treat-
ment failed. Furosemide was not used during the ﬁrst week of
life.
The baseline characteristics of the 66 studied premature in-
fants are presented in Table 1. In the study group the rate of
PDA closure was 93.9% (31 of 33 cases) while in the control
group the rate of PDA closure was 30.3% (10 of 33 cases) with
signiﬁcant difference in between. There was no reopening of
the ductus after closure had been achieved. No infant required
surgical ligation of the ductus in study group while in the con-
trol group 24.2% (8 of 33 cases) were required surgical ligation
(Table 2). Twenty-one newborns were treated with 1 dose of
ibuprofen, 9 were treated with 2 doses, and the remaining 3
were treated with 3 doses.7. Outcome and side effects
The survival rate at 1 month was 87.9% (29 of 33) in study
group I and 81.8% (27 of 33) in control group II with signiﬁ-Table 3 Outcome of the study infants (n= 22).
Variable Study group (no.
Death within 30 d (n) 4/33 (12.1%)
NEC (n) 1/33 (3.03%)
Localized bowel perforation 0
Sepsis (n) 6/33 (18.2%)
Extension of IVH during treatment (n)
Change from grade 1 to grade 2 0
Change from grade 2 to grade 3 1/33 (3.03%)
Change from grade 2 to grade 4 0
Change from grade 0 to grade 1 or higher 4/33 (12.1%)
PVL (n) 4/33 (12.1%)
Grade 1 (ﬂaring after day 7) 1/33 (3.03%)
Grade 2 3/33 (9.1%)
Grade 3 (cystic) 0
Respiratory outcome
BPD (n) 0
IPPV (d) Mean 11
CPAP (d) 0
Time to regain birth weight (d) 15.6 ± 4.8
Time to full enteral feeding (d) 20.2 ± 7.2
PVL, periventricular leukomalacia; BPD, broncopulmonary dysplasia;
positive airway pressure.
* Insigniﬁcant.
** Signiﬁcant.
Table 4 Changes in serum creatinine (mg/dL).
Stu
Day 1 (24 h after ibuprofen administration) 0.8
Day 2 (48 h after ibuprofen administration) 0.9
Day 3 (72 h after ibuprofen administration) 0.8
Pretreatment increase in serum creatinine from day 1 to day 3 p=
Comparison of creatinine between day 1 and day 2 p=
Comparison of creatinine between day 2 and day 3 p=
* Insigniﬁcant.cant differences in between P-value <0.001 (Table 3). The rate
of survival to discharge was 87.94% (29 of 33; Table 3). No
bronchopulmonary dysplasia (oxygen support at 36 weeks of
age) was observed in the study group, and there was no case
of tendency to bleed.
8. Renal function
There were no signiﬁcant differences in the levels of serum cre-
atinine before and after treatment with oral ibuprofen in both
study and control groups (P= .35; Table 4).
9. Discussion
The primary objective of the current study was to determine
whether orally administered ibuprofen treatment is efﬁcacious
in PDA closure in premature infants with RDS. Our results
showed oral ibuprofen to be effective and safe in PDA closure,
with 31 of our 33 (93.9%) study infants achieving a successful
outcome. This frequency of closure is in agreement with the
study done by Ohlsson et al. (2008) who done meta analysis= 33) Control group (no. = 33) p-Value
6/33 (18.2%) <0.001**
1/33 (3.03%) >0.05*
0
6/33 (18.2%) >0.05*
0
1/33 (3.03%) >0.05*
0
5/33 (15.4%) >0.05*
5/33 (15.4%) >0.05*
1/33 (3.03%) >0.05*
3/33 (9.1%) >0.05*
1/33 (3.03%) <0.001**
1/33 (3.03%) <0.001**
12 >0.05*
0 >0.05*
19 ± 6.4 <0.001**
25 ± 8.3 <0.001**
IPPV, intermittent positive pressure ventilation; CPAP, continuous
dy group (no. = 33) Control group (no. = 33) p-Value
8 ± 0.16 0.85 ± 0.18 >0.05*
1 ± 0.15 0.89 ± 0.26 >0.05*
± 0.14 0.81 ± 0.35 >0.05*
0.35* p= 0.36*
0.44* p= 0.46*
0.37* p= 0.38*
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of ibuprofen to indomethacin for the closure of a PDA. And
they ﬁnd there is no statistically signiﬁcant difference in the
effectiveness of ibuprofen compared to indomethacin in clos-
ing a PDA was found. Also, ibuprofen compared with indo-
methacin reduces the risk of oliguria and is associated with
lower serum creatinine levels following treatment (Ohlsson
et al., 2008).
Also, our result in agreement with the study done by Cherif
et al., they were studied 40 premature. Thirty-eight patients
(95%) achieved pharmacological closure. Two patients did
not respond to the treatment: One required surgical ligation
of the ductus, and the other patient received and well tolerated
ductal shunting (Cherif et al., 2007).
Also, in agreement with other study that done by Gimeno
Navarro and Zhongguo Dang and they were ﬁned oral ibupro-
fen is as effective as indomethacin for the treatment of PDA in
preterm infants (100%). Oral ibuprofen therapy is associated
with a lower incidence of NEC (Gournay et al., 2008; Gimeno
Navarro et al., 2005).
Our results higher than the 70% ﬁgure reported by Van
Overmeire’s group (Mahony et al., 1999) where ibuprofen
was administered intravenously, and also signiﬁcantly higher
compared with other studies in which indomethacin was
administered for PDA closure with a reported ductal closure
rate of between 71% and 77% (Gersony et al., 2004; Coceani
et al., 1998) and this explained by small number of studied
cases.
Ibuprofen was administered orally in our study; therefore,
there are theoretical concerns about direct gastrointestinal irri-
tability. In our study, the drug was given undiluted through a
feeding tube in a very small volume and followed by ﬂushing
with distilled water before ﬁnal dilution in the stomach. The
osmolarity of the ibuprofen suspension used in our study
was 320 mosmol/L, and the pH was 5.5, both of which are
not associated with gastrointestinal irritation. Most of the pre-
term infants in our study (n= 21) received only 1 dose of ibu-
profen, 9 patients received 2 doses, and only 3 infants received
3 doses. The administration of several doses of ibuprofen as an
antipyretic as presented and studied in other studies (Lesko
and Mitchell, 2005, 2004) was not associated with signiﬁcant
gastrointestinal tract problems.
Treatment with oral ibuprofen is both effective and safe,
and then it would have the advantages of more widespread
availability, simpler administration, and decreased cost.
The pharmacokinetics of oral ibuprofen among preterm in-
fants and infants older than 3 months have been studied and re-
ported (Kauffman and Nelson, 2002; Raju et al., 2007). The
ﬁndings indicate that ibuprofen is absorbed rapidly after oral
administration, and peak concentrations in plasma are observed
after 1–2 h. Among infants older than 3 months, the age of the
child does not signiﬁcantly inﬂuence the rate of absorption of
ibuprofen, the plasma concentration of the drug, or its rate of
elimination. With oral administration of ibuprofen, a small in-
ter-individual variability in the pharmacokinetics of the drug
is observed (Kauffman and Nelson, 2002; Raju et al., 2007).
Serum creatinine levels in our patients were within normal
range at all times, and no signiﬁcant differences between study
and control group so there was no contraindication for a sec-
ond or third dose of ibuprofen when it was needed. This might
be an explanation for the higher rate of pharmacologic ductal
closure observed in our study.The infant who died as a result of extreme prematurity (24th
gestational week) and extreme low birth weight (580 g) had no
deterioration in serum creatinine or in brain sonography.
IVH was observed in 7 infants (Table 1). The classiﬁcation
was changed from grade 2 to grade 3 in 1 and from grade 0 to
grade 1 or higher in 3 others (Table 3). IVH is a common com-
plication during the ﬁrst days of life in premature infants, and
its presence or extension therefore might be the natural history
of IVH or a complication of PDA in premature infants, and
not necessarily related to ibuprofen treatment as we see no sig-
niﬁcant differences between study and control groups.
10. Conclusion
Oral ibuprofen is an effective and safe alternative to intrave-
nous ibuprofen for PDA closure in premature infants.References
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